Table 1. Lung Cancer Patients' Profile in Poly Oncology Dr Soetomo General Hospital 2016-2017

		Total (n=240)	Adenocarcin oma (n=206, 85.8%)	SCC (n=24, 10%)	Adenosq uamous (n=4, 1.6%)	SCLC (n=6, 2.5%)
Age			63.6%)		1.0%)	
3.	<46	32 (13.3%)	29 (14%)	3 (12.5%)	0	0
	46-70	188 (78.3%)	154 (75%)	20 (83.3%)	4 (100%)	5 (83%)
	>70	25 (10.4%)	23 (11%)	1 (4%)	0	1 (16.7%)
Sex						
	Male	150 (62.5%)	123 (60%)	19 (79.1%)	3 (75%)	5 (83.8%)
	Female	90 (37.5%)	83 (40%)	5 (20.8%)	1 (25%)	1 (16.7%)
Smok	ing habits					
	Active smoker	133 (55%)	107 (52%)	18 (75%)	3 (75%)	5 (83.3%)
	Passive smoker	49 (20%)	45 (20%)	4 (17%)	0	0
	Non-smoker	58 (24%)	54 (27%)	2 (8.3%)	1 (25%)	1 (16.7%)
EGFR	Mutation					
	Positive	136 (57%)	133 (65%)	0	3 (75%)	0
	Negative	78 (33%)	73 (35%)	2 (8.3%)	1 (25%)	2 (33%)
Stage						
	Stage I	0	0	0	0	
	Stage II Stage III	3 (1.3%) 34 (14.5%)	3 (1.4%) 29 (14%)	0 2 (8.3%)	0 3 (75%)	
	Stage IV	197 (83%)	174 (84%)	2 (83%)	3 (75%) 1 (25%)	
	Limited Stage	137 (0070)	17 + (0 + 70)	22 (00/0)	1 (2370)	0
	Extensive Stage					6 (100%)
Symp	toms					
	Cough	169 (70.4%)				
	Dyspea	120 (50%)				
	Chest pain	118 (49.2%)				
	Hemoptisis	20 (8.3%)				
	Weight Loss	40 (16.7%)				
	Appetite Loss	22 (9.2%)				
	Hoarseness	2 (0.83%)				
	Lump neck	2 (0.83%)				
	Back pain	8 (3.3%)				
	Others	36 (15%)				
Γhera						
	Surgical	0	0	0	0	0
	Radiotherapy Chemothera	0 101 (42%)	0 72 (35%)	0 22 (92%)	0 1 (25%)	0
	py Targeted therapy	129 (54%)	129 (62.6%)	0	3 (75%)	6 (100%)
	Chemothera py and radiotherapy	1 (0.4%)	1 (0.49%)	0	0	0
	Chemothera py and targeted therapy	3 (1.25%)	2 (0.74%)	1 (4%)	0	0
	Radiotherapy and targeted therapy	1 (0.4%)	1 (0.49%)	0	0	0
	Paliative	1 (0.4%)	0	1 (4%)	0	0
	Reject	1 (0.4%)	1 (0.49%)	0	0	0